直到最近，由于选择有限和预后不良，诊断为局部晚期和转移性子宫内膜癌的患者在治疗中面临着巨大的挑战。肿瘤测序是其管理的重大进步。它导致了目前在临床实践中使用的癌症基因组图谱分类，并启动了几项创新治疗临床试验，主要针对信号通路、免疫检查点、DNA 完整性、生长因子、激素信号传导和代谢。许多临床试验正在研究这些靶向疗法的组合方法，以对抗肿瘤耐药性、细胞补偿机制和肿瘤多克隆性。这篇综述全面概述了晚期和转移性子宫内膜癌的历史、当前和有前景的治疗方法。它特别强调了靶向治疗和激素治疗以及免疫治疗的临床研究，反映了这种疾病治疗方式的不断发展。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Until recently, patients diagnosed with locally advanced and metastatic endometrial cancer faced significant challenges in their treatment due to limited options and poor prognostic outcomes. The sequencing of tumors has been a major advancement in its management. It has led to The Cancer Genome Atlas classification currently used in clinical practice and the initiation of several clinical trials for innovative treatments targeting principally signaling pathways, immune checkpoints, DNA integrity, growth factors, hormonal signaling, and metabolism. Numerous clinical trials are investigating a combinatorial approach of these targeted therapies to counter tumoral resistance, cellular compensatory mechanisms, and tumor polyclonality. This review provides a comprehensive overview of historical, current, and promising therapies in advanced and metastatic endometrial cancer. It particularly highlights clinical research on targeted and hormonal therapies, but also immunotherapy, reflecting the evolving landscape of treatment modalities for this disease.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.